ScripWho: Jemincare and Genentech What: The two companies have signed a licensing agreement around Jemincare’s androgen receptor degrader, JMKX002992. Why: The drug’s target is a confirmed disease dri
Medtech Insight[ Editor's note: A version of this article was originally published in Informa's Scrip .] Previously partnered on companion diagnostic development for ovarian and breast cancer, AstraZeneca will
ScripWho: AstraZeneca/Amoy Diagnostics What: Previously partnered on companion diagnostic development for ovarian and breast cancer, AstraZeneca and AmoyDx will attempt to develop such tools for optimiz